Sanofi and the WHO signed a first 5-year partnership to combat sleeping sickness in 2001. A third 5-year agreement was signed in 2011 with the goal to eliminate sleeping sickness and improve the management of leishmaniasis, Buruli ulcer and Chagas disease. Sanofi committed the same amount of financial backing (25 MUSD) and drug donations, bringing its total contribution to USD 75 million over 15 years (2001-2016).
These funds are dedicated to diseases management and control programs, including screening of population of endemic areas, medical staff training, disease awareness campaigns, logistics and infrastructure and surveillance of resistance to treatments.
|Location||North Africa and Middle East, Tunisia, Togo, Senegal, Niger, Morocco, Mauritania, Mali, Iran, Guinea, Ghana, Cote d Ivoire, Colombia, Central African Republic, Cameroon, Burkina Faso, Brazil, Benin, Argentina, Algeria, Afghanistan, West Africa, Latin America and Caribbean, Central Africa|